Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

New computational topology strategy to identify existing medicines for treating COVID-19

Researchers from the ESI International Chair of the CEU Cardenal Herrera University (CEU UCH) and ESI Group have just published in scientific journal Pharmaceutics a new computational topology strategy to identify existing medicines that could be applied to treat COVID-19 without waiting for the research and clinical trial phases required to develop a new medicine.

16 Jun 2021

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

A team of scientists from the United States has recently revealed how interactions between the SARS-CoV-2 nucleocapsid protein and the double-stranded RNA motifs impart distinct droplet properties that can support multiple viral functions. The study is currently available on the bioRxiv* preprint server.

16 Jun 2021

Reducing coronavirus-related mortality through senolytics

A study recently published in the journal Science explores the concept of senescent cells (SnC) having a hyperinflammatory response and the use of a class of small molecules called senolytics to combat this.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Collecting FEMA funeral money takes some tenacity — and help

As a funeral director at Ingold Funeral and Cremation in Fontana, California, Jessica Rodriguez helps families say goodbye to their loved ones. "We serve predominantly Latino families, most of them second- and third-generation" residents, said Rodriguez. "We do have quite a few that are first-generation, that don't speak any English."

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

A new approach focusing on cellular repair may be an effective strategy to address the pandemic.

16 Jun 2021

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

A team of researchers from the US and UK used the AGM intranasal model of SARS-CoV-2 infection to determine differences between a contemporary SARS-CoV-2 D614G variant circulating in summer 2020 and the B.1.1.7 UK variant of concern that emerged in late 2020.

16 Jun 2021

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Cissampelos pareira (Cipa), also known as velvetleaf, is a widely used hormone modulator used to treat reproductive disorders and fever. Research has shown that it can inhibit three serotypes of Dengue virus (DENV) and affect various hormones.

16 Jun 2021

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

The researchers found that individuals with registered diphtheria or tetanus vaccinations were less likely to develop severe COVID-19 than people who had only received other vaccinations. The results of this study are posted to the medRxiv* preprint server.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

COVID-19 Vaccine DSMB can serve as model for future situations

Clinical evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic that killed or sickened millions was unprecedented in terms of urgency and scope.

16 Jun 2021

COST Actions provide space to grow ideas in science and technology fields

Over the years, COST Actions have become one the main instrument for research collaboration in Europe.

15 Jun 2021

New AI model could help predict which viruses are likely to spread from animals to humans

A new model that applies artificial intelligence to carbohydrates improves the understanding of the infection process and could help predict which viruses are likely to spread from animals to humans.

15 Jun 2021

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

At the close of this year’s G7 Leaders’ summit, the Prime Minister of the United Kingdom of Great Britain and Northern Ireland announced a donation of an additional 870 million vaccine doses from attendees, with the majority to be delivered through COVAX, the vaccines pillar of the Access to COVID 19 Tools Accelerator, within the next year.

15 Jun 2021

Global leaders pledge to share COVID-19 vaccine doses internationally at the G7 summit

In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.

15 Jun 2021

Inclusion of biological uncertainty, latest data can improve prediction accuracy of epidemic models

The inclusion of biological uncertainty and the latest case data can significantly improve the prediction accuracy of standard epidemiological models of virus transmission, new research led by KAUST and the Kuwait College of Science and Technology (KCST) has shown.

15 Jun 2021

Adolescents feel helpless when exposed to online and media-based vicarious racism

This past year has been transformational in terms of not only a global pandemic but a sustained focus on racism and systemic injustice.

15 Jun 2021

Pandemic News and Research

Further Reading

New computational topology strategy to identify existing medicines for treating COVID-19

Scientists reveal the mechanism of liquid-liquid phase separation of SARS-CoV-2 nucleocapsid

Reducing coronavirus-related mortality through senolytics

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Collecting FEMA funeral money takes some tenacity — and help

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

Anti-viral treatment can stop the spread of lab modeled SARS-CoV-2 by 99.5%

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

COVID-19 Vaccine DSMB can serve as model for future situations

COST Actions provide space to grow ideas in science and technology fields

New AI model could help predict which viruses are likely to spread from animals to humans

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

Global leaders pledge to share COVID-19 vaccine doses internationally at the G7 summit

Inclusion of biological uncertainty, latest data can improve prediction accuracy of epidemic models

Adolescents feel helpless when exposed to online and media-based vicarious racism

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News